208 related articles for article (PubMed ID: 19655335)
1. Drug development costs when financial risk is measured using the Fama-French three-factor model.
Vernon JA; Golec JH; Dimasi JA
Health Econ; 2010 Aug; 19(8):1002-5. PubMed ID: 19655335
[TBL] [Abstract][Full Text] [Related]
2. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
3. The cost of drug development: a systematic review.
Morgan S; Grootendorst P; Lexchin J; Cunningham C; Greyson D
Health Policy; 2011 Apr; 100(1):4-17. PubMed ID: 21256615
[TBL] [Abstract][Full Text] [Related]
4. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
5. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
Refoios Camejo R; McGrath C; Herings R
Health Policy; 2011 Apr; 100(1):18-24. PubMed ID: 20864202
[TBL] [Abstract][Full Text] [Related]
6. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
7. The calculus of cures.
Kocher R; Roberts B
N Engl J Med; 2014 Apr; 370(16):1473-5. PubMed ID: 24571723
[No Abstract] [Full Text] [Related]
8. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
9. Cost of innovation in the pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
[TBL] [Abstract][Full Text] [Related]
10. Risky business--health care finance and the VA.
Bromley HR
Physician Exec; 2008; 34(3):42-4, 46-7. PubMed ID: 18605271
[TBL] [Abstract][Full Text] [Related]
11. What's your real cost of capital?
McNulty JJ; Yeh TD; Schulze WS; Lubatkin MH
Harv Bus Rev; 2002 Oct; 80(10):114-21, 130. PubMed ID: 12389465
[TBL] [Abstract][Full Text] [Related]
12. Opinion: development of new drugs is still a risky business.
Franks B
N J Med; 2002; 99(1-2):60, 59. PubMed ID: 15326736
[No Abstract] [Full Text] [Related]
13. Objective risk adjustment improves calculated ROI for capital projects.
Holmes RL; Schroeder RE; Harrington LF
Healthc Financ Manage; 2000 Dec; 54(12):48-52. PubMed ID: 11141687
[TBL] [Abstract][Full Text] [Related]
14. Who pays what in drug development.
Love J
Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
[No Abstract] [Full Text] [Related]
15. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
16. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
Falagas ME; Fragoulis KN; Karydis I
PLoS One; 2006 Dec; 1(1):e11. PubMed ID: 17183637
[TBL] [Abstract][Full Text] [Related]
17. The $2.6 billion pill--methodologic and policy considerations.
Avorn J
N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
[No Abstract] [Full Text] [Related]
18. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
19. Capital investment analysis: three methods.
Gapenski LC
Healthc Financ Manage; 1993 Aug; 47(8):60-6. PubMed ID: 10145854
[TBL] [Abstract][Full Text] [Related]
20. [Development of new drugs is too expensive].
Andreasen J
Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
[No Abstract] [Full Text] [Related]
[Next] [New Search]
